Income Statement Jiangsu Hengrui Pharmaceuticals Co.,Ltd
Equities
600276
CNE0000014W7
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 63.17 CNY | -0.69% |
|
-1.06% | +6.04% |
| Jan. 12 | Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug | MT |
| Jan. 12 | Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 27.61B | 25.78B | 21.21B | 22.38B | 25.01B | |||||
Other Revenues, Total | 122M | 125M | 62.25M | 443M | 2.98B | |||||
Total Revenues | 27.73B | 25.91B | 21.28B | 22.82B | 27.98B | |||||
Cost of Goods Sold, Total | 3.36B | 3.76B | 3.5B | 3.56B | 3.88B | |||||
Gross Profit | 24.38B | 22.15B | 17.77B | 19.26B | 24.1B | |||||
Selling General & Admin Expenses, Total | 12.87B | 12.24B | 9.65B | 9.99B | 10.89B | |||||
Provision for Bad Debts | 9.36M | -3.87M | 26.02M | -15.77M | -28.67M | |||||
R&D Expenses | 4.99B | 5.94B | 4.89B | 4.95B | 6.58B | |||||
Other Operating Expenses | 239M | 190M | 190M | 149M | 182M | |||||
Other Operating Expenses, Total | 18.11B | 18.37B | 14.76B | 15.08B | 17.63B | |||||
Operating Income | 6.27B | 3.78B | 3.01B | 4.18B | 6.48B | |||||
Interest Expense, Total | - | -4.71M | -6.49M | -5.9M | -5.56M | |||||
Interest And Investment Income | 632M | 581M | 773M | 477M | 608M | |||||
Net Interest Expenses | 632M | 576M | 766M | 471M | 602M | |||||
Currency Exchange Gains (Loss) | -102M | -22.42M | 93.19M | 7.9M | -24.04M | |||||
Other Non Operating Income (Expenses) | -3.89M | -2.2M | -1.37M | 736K | -612K | |||||
EBT, Excl. Unusual Items | 6.8B | 4.33B | 3.87B | 4.66B | 7.05B | |||||
Gain (Loss) On Sale Of Investments | 16.5M | 36.23M | 76.5M | -107M | 109M | |||||
Gain (Loss) On Sale Of Assets | 699K | 3.37M | 4.23M | -3.05M | 5.4M | |||||
Asset Writedown | - | -1.73M | -130M | -70M | -4.94M | |||||
Other Unusual Items | 80.67M | 101M | 145M | 192M | 7.55M | |||||
EBT, Incl. Unusual Items | 6.9B | 4.47B | 3.97B | 4.67B | 7.17B | |||||
Income Tax Expense | 587M | -17.72M | 153M | 389M | 833M | |||||
Earnings From Continuing Operations | 6.31B | 4.48B | 3.82B | 4.28B | 6.34B | |||||
Net Income to Company | 6.31B | 4.48B | 3.82B | 4.28B | 6.34B | |||||
Minority Interest | 19.49M | 46.19M | 91.23M | 24.62M | -468K | |||||
Net Income - (IS) | 6.33B | 4.53B | 3.91B | 4.3B | 6.34B | |||||
Net Income to Common Incl Extra Items | 6.33B | 4.53B | 3.91B | 4.3B | 6.34B | |||||
Net Income to Common Excl. Extra Items | 6.33B | 4.53B | 3.91B | 4.3B | 6.34B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.99 | 0.71 | 0.61 | 0.68 | 1 | |||||
Basic EPS - Continuing Operations | 0.99 | 0.71 | 0.61 | 0.68 | 1 | |||||
Basic Weighted Average Shares Outstanding | 6.38B | 6.38B | 6.4B | 6.33B | 6.34B | |||||
Net EPS - Diluted | 0.99 | 0.71 | 0.61 | 0.68 | 1 | |||||
Diluted EPS - Continuing Operations | 0.99 | 0.71 | 0.61 | 0.68 | 1 | |||||
Diluted Weighted Average Shares Outstanding | 6.38B | 6.38B | 6.4B | 6.33B | 6.34B | |||||
Normalized Basic EPS | 0.67 | 0.43 | 0.39 | 0.46 | 0.7 | |||||
Normalized Diluted EPS | 0.67 | 0.43 | 0.39 | 0.46 | 0.7 | |||||
Dividend Per Share | 0.17 | 0.16 | 0.16 | 0.2 | 0.2 | |||||
Payout Ratio | 16.07 | 23.54 | 26 | 23.77 | 20.12 | |||||
American Depositary Receipts Ratio (ADR) | 2 | 2 | 2 | 2 | 2 | |||||
Supplemental Items | ||||||||||
EBITDA | 6.72B | 4.27B | 3.55B | 4.83B | 7.19B | |||||
EBITA | 6.28B | 3.79B | 3.03B | 4.2B | 6.54B | |||||
EBIT | 6.27B | 3.78B | 3.01B | 4.18B | 6.48B | |||||
EBITDAR | 6.73B | 4.31B | 3.56B | 4.87B | 7.31B | |||||
Total Revenues (As Reported) | 27.73B | 25.91B | 21.28B | 22.82B | 27.98B | |||||
Effective Tax Rate - (Ratio) | 8.51 | -0.4 | 3.87 | 8.34 | 11.61 | |||||
Total Current Taxes | 568M | 75.66M | 176M | 488M | 856M | |||||
Total Deferred Taxes | 18.79M | -93.38M | -22.17M | -98.47M | -23.14M | |||||
Normalized Net Income | 4.27B | 2.75B | 2.51B | 2.93B | 4.41B | |||||
Interest on Long-Term Debt | - | 4.71M | 5.55M | 4.27M | 4.54M | |||||
Non-Cash Pension Expense | - | - | 125M | 17.18M | 88.83M | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | - | - | - | - | - | |||||
Selling and Marketing Expenses | 9.8B | 9.38B | 7.35B | 7.58B | 8.34B | |||||
General and Administrative Expenses | 3.07B | 2.86B | 2.31B | 2.42B | 2.56B | |||||
Research And Development Expense From Footnotes | 4.99B | 5.94B | 4.89B | 4.95B | 6.58B | |||||
Net Rental Expense, Total | 13.24M | 41.53M | 15.95M | 42.58M | 120M | |||||
Imputed Operating Lease Interest Expense | - | - | 1.1M | 2.8M | 57.51M | |||||
Imputed Operating Lease Depreciation | - | - | 14.85M | 39.78M | 62.33M | |||||
Stock-Based Comp., R&D Exp. (Total) | 123M | 95.31M | 14.79M | 78.04M | 94.28M | |||||
Stock-Based Comp., S&M Exp. (Total) | 152M | 130M | 3.27M | 57.75M | 69.98M | |||||
Stock-Based Comp., G&A Exp. (Total) | 38.57M | 24.25M | 3.27M | 17.43M | 25.65M | |||||
Stock-Based Comp., Other (Total) | 19.53M | 28.26M | 10.74M | 13.44M | 19.34M | |||||
Total Stock-Based Compensation | 332M | 278M | 32.06M | 167M | 209M |
Select your edition
All financial news and data tailored to specific country editions
















